CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) announced today the issuance of a U.S. patent for its lead product candidate DX-88, a non-naturally occurring kallikrein inhibitor, and its uses. U.S. Patent No. 7,235,530 (issued June 26, 2007), relates to the company’s DX-88 program in on-pump cardiothoracic surgery (CTS), and provides Dyax with patent claims for the use of DX-88 in combination with anti-thrombolytic agents for preventing or reducing blood loss in patients undergoing invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. Dyax now has eight issued U.S. patents covering DX-88 as well as other related kallikrein inhibitors, and their uses. The company is currently conducting a Phase 2 trial for DX-88 in on-pump CTS.
